Namrata

Namrata, on behalf of Vik Chopra, asked about the key milestones the company is focusing on to ensure a strong return to market for SurgiMend, with the Braintree facility expected to resume operations mid-2026 and SurgiMend relaunching in Q4. She also inquired about the outlook for the recovery and ramp of PriMatrix and DuraRepair in 2026.

Answer

EVP and CFO Lea Knight confirmed Braintree is on track for operationalization by the end of June, with remaining milestones focused on process validations before inventory build. She noted the early relaunch of DuraRepair and PriMatrix in Q4 2025, with strong customer reception, and expects them to be significant contributors in 2026, providing valuable learnings for the upcoming SurgiMend relaunch.

Namrata asked about the key milestones Integra is focused on to ensure a strong return to market for SurgiMend, given Braintree is expected to resume mid-2026 and SurgiMend relaunching in Q4. She also inquired about the outlook for PriMatrix and DuraRepair's recovery and ramp in 2026, acknowledging their historical contributions.

Answer

Lea Knight, Chief Financial Officer, stated that Braintree is on track for operationalization by the end of June, with remaining milestones primarily process validations before inventory build. Regarding PriMatrix and DuraRepair, she noted their early relaunch in Q4 2025 (12 months ahead of plan) has seen strong customer reception. Integra expects a measured ramp for these products, using learnings for the upcoming SurgiMend relaunch, and anticipates them to be strong contributors in 2026.